| | | |   | | | | By Ed Silverman and Jonathan Wosen Alex Hogan/STAT, Adobe Gilead and Johnson & Johnson have been hit by a sweeping and sophisticated counterfeit drug scheme involving HIV medicines. Read More | | By Ed Silverman FABRICE COFFRINI/AFP/Getty Images Documents reviewed by STAT illustrate issues at a Novartis facility where production of a cancer treatment was halted this month. Read More | | By Nicholas Florko Adobe The American Medical Association is fighting an otherwise popular bill that would require training doctors about opioid use disorder. Read More | | Sponsor content by REGULATORY AFFAIRS PROFESSIONALS SOCIETY (RAPS) How will the rapidly changing regulatory landscape affect your submissions? Understanding the implications of new and changing regulations in bringing drug products to market is essential for regulatory affairs professionals. Build a solid foundation of the latest knowledge with a Regulatory Affairs Certificate in Pharmaceuticals, where you'll learn how to navigate the rapidly evolving regulatory landscape. The certificate program features a series of nine self-paced online courses, including five electives spanning the topical areas of pharmaceuticals, quality, clinical, biologics, and the regulatory profession. Learn more. | | By Ed Silverman BRYAN R. SMITH/AFP via Getty Images A former AstraZeneca communications executive was accused of insider trading in connection with a partnership with Daiichi Sankyo. Read More | |
No comments